NSE: SUNPHARMA | BSE: 524715

Mid-range Performer

Download real time

1721.10 1.40 (0.08%)

923.0K NSE+BSE Volume

NSE 01 Jan, 2026 3:31 PM (IST)

412,949.5

Market Cap

Market Leader

Beta 1Year

Very Low volatility

Sun Pharmaceutical Industries Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SUNPHARMA, BSE:524715 Sun Pharmaceutical Industries Ltd.

Search Inside the pdf :

Sun Pharmaceutical Industries Ltd.

07 Nov 2025

1721.10

0.08%

Steady quarter with broad-based growth and resilient margins.

Accumulate: Sun Pharmaceutical Industr...

Deven Choksey

Sun Pharma’s outlook remains strong, driven by high-margin and innovative products. India growth will be led by new launches and upcoming GLP-1 therapies, EM by branded generics, and RoW by complex products. In the U.S., momentum will be supported by LEQSELVI ramp-up, Unloxcyt launch, and continued strength in ILUMYA and CEQUA.

Sun Pharmaceutical I.. has an average target of 1921.38 from 8 brokers.

Sun Pharmaceutical Industries Ltd.

06 Nov 2025

1721.10

0.08%

Sun Pharma

Buy: Sun Pharmaceutical Industr...

Target

ICICI Direct

Q2FY26- Decent numbers despite flat US growth - Revenues grew ~9% YoY to 14478.3 crore driven mainly by growth in India, global specialty portfolio (now named as Innovative products), RoW and Emerging Markets. India growth was strong at 11% to 4735 crore. The US remained flat YoY with a revenue of 4329 crore due to weakness in generics which was made good by Innovative traction to some extent. RoW markets reported growth of ~23% to 2041 crore, mainly due to growth in both generics and specialty. Emerging markets grew ~16% to 2837 crore,...

Sun Pharmaceutical Industries Ltd. is trading above its 200 day SMA of 1697.5

Sun Pharmaceutical Industries Ltd.

06 Nov 2025

1721.10

0.08%

Strong margin performance continues; all markets in fine fettle

Buy: Sun Pharmaceutical Industr...

Target

Emkay

Sun’s 2QFY26 EBITDA was ahead of the street and our estimates (by ~12%), on the back of a marginally higher gross margin and lower R&D spend.

Sun Pharmaceutical Industries Ltd. is trading below its 30 day SMA of 1776.0

Sun Pharmaceutical Industries Ltd.

06 Nov 2025

1721.10

0.08%

Sun Pharmaceutical Industries (SUNP IN) Q2FY26 Result Update ...

Buy: Sun Pharmaceutical Industr...

Prabhudas Lilladhar

Sun Pharmaceutical Industries Ltd. is trading below its 30 day SMA of 1776.0

Sun Pharmaceutical Industries Ltd.

06 Nov 2025

1721.10

0.08%

Superior show in innovative/branded portfolios

Buy: Sun Pharmaceutical Industr...

Motilal Oswal

Sun Pharma (SUNP) delivered in-line revenue/EBITDA in 2QFY26. Earnings came in below our estimates largely due to lower other income.

Sun Pharmaceutical Industries Ltd. is trading above its 200 day SMA of 1697.5

Sun Pharmaceutical Industries Ltd.

23 Sep 2025

1721.10

0.08%

Well poised to sustain growth in focus segments

Buy: Sun Pharmaceutical Industr...

Motilal Oswal

Management said that SUNP aims to sustain its outperformance in the domestic formulation (DF) segment through increased doctor engagement, new launches, addition of field force and strengthening the brand recall of its existing products.

Sun Pharmaceutical Industries Ltd. is trading below its 30 day SMA of 1776.0

Sun Pharmaceutical Industries Ltd.

05 Aug 2025

1721.10

0.08%

SUN PHARMA

Buy: Sun Pharmaceutical Industr...

Recommendation Target

Geojit BNP Paribas

Sun Pharma performed resiliently, driven by strong prescription momentum in India, *over or under performance to benchmark index strategic rural field force expansion and focused execution in its US specialty business. The management is actively steering pipeline progression with regulatory filings across key therapy areas backed by sustained research and development intensity. The company maintains a calibrated stance on US manufacturing, given adequate capacity and exemption from the current tariff measures. Notably, its firstmover positioning in India's GLP-1 space and accelerated launch of readiness for...

Number of FII/FPI investors decreased from 1326 to 1225 in Sep 2025 qtr

Sun Pharmaceutical Industries Ltd.

01 Aug 2025, 12:00AM

1721.10

0.08%

Sun Pharmaceutical Industries (SUNP IN) Q1FY26 Result Update ...

Buy: Sun Pharmaceutical Industr...

Target

Prabhudas Lilladhar

Reiterate its $100mn expenses towards new launches of specialty in FY26. Sun Pharma (SUNP) Q1FY26 EBIDTA (+11% YoY) was 7% above our estimates aided by higher specialty sales and lower opex. Over last few years SUNP dependency on US generics has reduced and company's growth is more functional on specialty, RoW and domestic pharma that has strong growth visibility. Though FY26 expenses (an additional $100mn spend) is likely to remain elevated given company are in investment phase to ramp up specialty...

Promoters pledged 0.09% of shares in last quarter. Total pledge stands at 0.97% of promoter holdings

Sun Pharmaceutical Industries Ltd.

31 Jul 2025, 12:00AM

1721.10

0.08%

Innovative/branded portfolio drives earnings

Buy: Sun Pharmaceutical Industr...

Target

Motilal Oswal

Sun Pharmaceutical Industries’ (SUNP) 1QFY26 revenue and EBITDA were 3%/9% better than our estimates. However, Adj. PAT was lower than expected (6% miss) due to lower other income and a higher tax rate.